Caliway Biopharmaceuticals Co., Ltd. (6919) Stock Price, Fundamentals & Analysis

What 6919 does

Caliway Biopharmaceuticals Co., Ltd. (6919) develops drugs for aesthetic medicine and chronic inflammation. The company is best known for CBL-514, an investigational drug currently in Phase 2 clinical trials for non-surgical fat reduction, Dercum's disease, and cellulite treatment. It is also developing CBA-539 in the preclinical stage for central obesity, hyperpigmentation, and skin aging, and it offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan. It trades on the Taiwan Stock Exchange under the symbol 6919.

Key numbers explained

• The current price is 80.1 TWD, down 0.62% today.
• The market capitalization of 124.67B TWD reflects the total market value of all outstanding shares.
• The forward P/E ratio of 14.9 compares the price to expected future earnings; a lower figure can suggest lower relative valuation expectations.
• Earnings per share over the trailing 12 months is -0.17 TWD, indicating the company reported a net loss on a per-share basis.
• The dividend yield is 0%, and 0% of earnings are paid out as dividends, meaning the company currently does not distribute cash to shareholders.
• Beta of 1.09 suggests the stock's price tends to move slightly more than the overall market.
• The 52-week range is 75.1 – 195, with the price down 56.6% over the past year.
• Revenue for the trailing 12 months is 29.39M TWD, down 70.8% year over year.
• Operating margin of -7,377.6% and profit margin of 0% show the company is operating at a significant loss relative to revenue.
• The debt-to-equity ratio of 1.2 means the company carries slightly more debt than equity.
• Price-to-book of 13.53 compares the market price to the company's book value per share.

What to watch

As a clinical-stage biotechnology company, Caliway Biopharmaceuticals Co., Ltd. (6919) is sensitive to clinical trial results and regulatory milestones. Investors often track the progress of its lead asset, CBL-514, through Phase 2 studies for non-surgical fat reduction and Dercum's disease. The company's small revenue base and negative margins mean that capital raises and partnership announcements can materially affect the share price. Broader movements in the healthcare and biotechnology sectors, as well as shifts in the Taiwan Stock Exchange index, can also influence trading activity. For comparison, investors may look at peers such as Shanghai Pharmaceuticals Holding (601607), Sun Pharma (SUNPHARMA), M3, Inc. (2413), Amplifon (AMP), Hualan Biological Engineering (002007), Hanmi Science (008930), or Kalbe Farma Tbk. (KLBF).